TORONTO, Dec. 10 /CNW/ - SQI Diagnostics Inc. (TSX-Venture: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced positive results from an internal performance study of SQiDworks(TM), its proprietary automated multiple-biomarker test platform and QuantiSpot(TM), its corresponding microarray consumable. The trial results demonstrated that SQI’s automated system generates equivalent results to current technologies, while providing substantial time and labour savings.
